Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514553000 - Radical -XH acid, or anhydride, acid halide or salt thereof (X is chalcogen) DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514561000 Nitrogen other than as nitro or nitroso nonionically bonded 553
514558000 Higher fatty acid or salt thereof 349
514568000 Benzene ring nonionically bonded 201
514574000 Polycarboxylic acid or salt thereof 58
514572000 Cyclic carboxylic acid containing three to five carbons or cyclic percarboxylic acid containing three to five carbons or salt thereof 21
Entries
DocumentTitleDate
20090247630DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID COMPOUND AND AT LEAST ONE FILM-FORMING AGENT AND TREATMENT OF KERATINIZATION DISORDERS THEREWITH - Topically applicable, reduced-irritant dermatological/cosmetic compositions useful for the prevention/treatment of a variety of keratinization disorders, for example acne vulgaris, contain at least one naphthoic acid compound essentially uniformly distributed therethrough and an amount of at least one hydrophilic film-forming agent, formulated into topically applicable, physiologically acceptable media therefor.10-01-2009
20090215893Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin - The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin-inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and to further provide an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor agent, pore-shrinking agent, or rough skin preventing/amaliorating agent comprises one, two, or more compounds selected from the group consisting of α-amino acid derivatives and salts thereof. The external composition for skin comprises the one, two, or more compounds selected from the group consisting of α-amino acid derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent.08-27-2009
20120202880MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.08-09-2012
20090082444Compositions for the Treatment of Blood Disorders - The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders.03-26-2009
20090054522Hair Care Product - With an object of discovering a substance having a testosterone 5α-reductase inhibiting action, a hair papilla cell growth promoting action, a fibroblast growth factor-7 production promoting action, a vascular endothelial growth factor production promoting action or a bone morphogenetic protein-2 production promoting action, and of providing a hair care product having this substance blended therein, and a hair growth tonic, a testosterone 5α-reductase inhibitor, a hair papilla cell growth promoter, a fibroblast growth factor-7 production promoter, a vascular endothelial growth factor production promoter and a bone morphogenetic protein-2 production promoter each having this substance as an active ingredient thereof, a hair care product of the present invention is made to contain corosolic acid therein, and each of a hair growth tonic, a testosterone 5α-reductase inhibitor, a hair papilla cell growth promoter, a fibroblast growth factor-7 production promoter, a vascular endothelial growth factor production promoter and a bone morphogenetic protein-2 production promoter of the present invention is made to contain corosolic acid as an active ingredient thereof.02-26-2009
20130046019Methods of Treatment Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production - The present invention provides methods for preventing or treating infections, especially bacterial infections, by administering selective inhibitors of ATP production to inhibit glycolytic enzymes, such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH). As such, the present invention further provides methods for preventing or treating inflammation and sepsis associated with infections, as well as increased wound healing and decreased wound scarring.02-21-2013
20130158116Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the 06-20-2013
20100076081METHOD FOR PRODUCING SALT OF 4-SULFINYLAMINO-1-CYCLOHEXANECARBOXYLIC ACID - Disclosed is a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid. Also disclosed is a method for producing a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid.03-25-2010
20100076082New Cleaning, Descaling and Disinfecting Composition for Dialysis Generators - Composition comprising, per 100% of its mass, essentially: from 0.50% by mass to 1.50% by mass of peracetic acid, from 3.00% by mass to 15.00% by mass of hydrogen peroxide, from 3.00% by mass to 15.00% by mass of acetic acid, from 0.10% by mass to 1.00% by mass of concentrated nitric acid, from 0.001% by mass to 0.20% by mass of nonionic surfactant, from 0.01% by mass to 0.10% by mass of amine oxide, from 0.01% by mass to 0.20% by mass of stabilizer, and water to make up to 100% by mass; use thereof for cleaning, descaling and disinfecting dialysis equipment between two successive dialysis sessions, without additional treatment other than rinsing of said dialysis equipment with osmosed water; methods for the use thereof.03-25-2010
20120245228Methods and compositions for the generation of peracetic acid on site at the point-of-use - Methods and compositions for the generation of a peroxyacetic acid sanitizer in proximity to the point-of-use are disclosed. These methods comprise introducing a hydrogen peroxide-acetyl precursor solution to water, mixing, and then adding an aqueous source of a alkali metal or earth alkali metal hydroxide. Triacetin is a preferred acetyl precursor and is converted rapidly and with a high conversion rate into peracetic acid. These methods produce solutions with a high level of peracetic acid. Methods for preparing the hydrogen peroxide-acetyl precursor solution are also provided. Also disclosed are solid compositions comprising a liquid acetyl precursor, a water-soluble source of hydrogen peroxide, and a water-soluble source of alkalinity. The solid composition is a freely-flowable solid that is used as a bleaching agent and a stain remover for the treatment of articles such as fabrics, dentures, textile garments, and equipment used in the food and beverage industry.09-27-2012
20130079408PERACID AND 2-HYDROXY ORGANIC ACID COMPOSITIONS AND METHODS FOR TREATING ITEMS - Methods and compositions for treating items to control microorganisms are provided. The method treats produce by contacting the surface of the item with an aqueous composition comprising i) an organic peracid of the formula RC(O)OOH wherein R is methyl, ethyl, n-propyl, or s-propyl; ii) a 2-hydroxy organic acid selected from tartaric acid, citric acid, malic acid, mandelic acid, and lactic acid; and iii) water; wherein the aqueous composition has a pH from 2.5 to 6.0.03-28-2013
20100041753INHIBITION OF BIOFILM FORMATION - The present invention relates to compositions and methods for reducing or inhibiting biofilm comprising modulating expression of a cysB gene in a cell. The invention also provides methods for modulating the expression of a cysB, cysD, cysI, cysJ, cysK, and ybiK. The invention further provides methods for identifying gene(s) involved in biofilm formation and for identifying biofilm inhibitors.02-18-2010
20100041752Production of peracids using an enzyme having perhydrolysis activity - A method is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity derived from 02-18-2010
20090062389In-Shower Lotion Compositions Comprising Up to 10% Free Fatty Acids Wherein Ratio of Unsaturated to Saturated Fatty Acids is at Least 1:1 - This invention relates to rinse-off skin conditioning compositions comprising relatively low amounts of oil/emollient and relatively low amounts of aqueous phase stabilizer/structurant. Use of unsaturated fatty acid (or at least minimum amount of unsaturated fatty acid as percentage of total fatty acid) has been found to result in unexpectedly high hydration. In a second embodiment, use of branched fatty acid (at minimum amount branched as percentage of total) also results in superior hydration. Also mixtures of unsaturated and branched fatty acids can be used.03-05-2009
20100093862POTENTIATION OF CELLULAR IMMUNITY USING HISTONE DEACETYLASE (HDAC) INHIBITORS. - [Technical Problem] The present invention provides an enhancer of cellular immunity, and provides applications to carcinogenesis or preventive therapy against cancer recurrence, immunotherapy for cancer, treatment for pathogenic microorganism infection, and the like.04-15-2010
20130046018DIETARY SUPPLEMENTS CONTAINING TERPENOID ACIDS OF MASLINIC ACID OR OLEANOLIC ACID AND PROCESS FOR ENHANCING MUSCLE MASS IN MAMMALS - A process for increasing lean body mass in a mammalian subject is provided that includes administering to the subject a purified quantity of maslinic acid, oleanolic acid, or a combination thereof. The administration can be orally and benefits from ingestion of an amino acid source such as dietary protein, oligopeptides, or amino acids. Administration within 2 hours of muscle-degrading exercise or on a daily basis for a period of time increases lean body mass.02-21-2013
20130090382METHODS, ASSAYS, AND KITS RELATED TO DICHLOROACETATE (DCA) - Embodiments of the present disclosure provide for methods, assays, and kits for predicting dosing for subjects. In addition, embodiments of the present disclosure include methods, assays, and kits, of determining if a patient can effectively metabolize one or both of phenylalanine and tryrosine.04-11-2013
20130072563PERACID AND 2-HYDROXY ORGANIC ACID COMPOSITIONS AND METHODS FOR SANITATION AND DISEASE PREVENTION - Methods and compositions for treating living surfaces to control microorganisms are provided. The method treats produce by contacting a living surface with an aqueous solution comprising i) an organic peracid of the formula RC(O)OOH wherein R is methyl, ethyl, n-propyl, or s-propyl; ii) a 2-hydroxy organic acid selected from tartaric acid, citric acid, malic acid, mandelic acid, and lactic acid; and iii) water.03-21-2013
20090270501COMPOSITION AND METHOD FOR INCREASING THE ANABOLIC STATE OF MUSCLE CELLS - A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle by substantially simultaneously maintaining blood and muscle physiological pH levels as well as increasing cellular concentrations of branched-chain amino acids. Both a composition and a method are provided by the present disclosure.10-29-2009
20130065959SANITIZING MEAT WITH PERACID AND 2-HYDROXY ORGANIC ACID COMPOSITIONS - Methods and compositions for treating items to control microorganisms are provided. The method treats produce by contacting the surface of an item with an aqueous solution comprising i) an organic peracid of the formula RC(O)OOH wherein R is methyl, ethyl, n-propyl, or s-propyl; ii) a 2-hydroxy organic acid selected from tartaric acid, citric acid, malic acid, mandelic acid, and lactic acid; and iii) water wherein the aqueous solution has a pH from 2.5 to 6.0.03-14-2013
20130065958METHODS FOR DISINFECTING OR STERILIZING ARTICLES - Disclosed herein are materials and methods for reducing, preventing, or eliminating the biological contamination of surfaces in spaces that are reasonably partitioned, defined or contained. A reagent that includes peroxides or molecules that includes peroxide bonds are contacted with at least one surface of an article. Some of these methods include disinfection within an apparatus and may include the step of volatilizing the peroxide bond containing agent, through, for example, vapour pressure and vaporization or evaporation effects, the addition of volatilization aids, or passive or assisted diffusion at modest temperatures and relatively long exposure times measured in some embodiments on the order of hours, days, or months. In some embodiments a liquid that includes a peroxide moiety is added (for example, during manufacture or subsequently) to a package, container, or any other reasonably partitioned or contained volume and allowed to migrate within the confined space for a period of time sufficient to disinfect the inner surfaces of the container and articles it contains.03-14-2013
20100087529PERHYDROLASES FOR ENZYMATIC PERACID GENERATION - Disclosed herein are variants enzymes that are structurally classified as CE-7 enzymes and have perhydrolysis activity. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned variant enzymes as well as methods and compositions comprising the variant enzymes. Further, disinfectant formulations comprising the peroxycarboxylic acids produced by the processes described herein are provided.04-08-2010
20100087530METHODS FOR WASHING POULTRY DURING PROCESSING WITH MEDIUM CHAIN PEROXYCARBOXYLIC ACID COMPOSITIONS - The present invention relates to methods for reducing microbial contamination on poultry, or on surfaces used in processing poultry, employing compositions including medium chain peroxycarboxylic acid, and to the compositions. The methods include applying a medium chain peroxycarboxylic acid composition to poultry or to the surfaces.04-08-2010
20090221704PROCESS FOR THE PREPARATION OF PEROXY ACIDS - The present invention relates to a process for the preparation of a solution comprising a first peroxy acid comprising performic acid and a second peroxy acid, said process comprising forming a carboxylic acid solution comprising a first carboxylic acid comprising formic acid, a second carboxylic acid and hydrogen peroxide, wherein the amount of formic acid is from 0.5 to 20% by weight of the amount of the second carboxylic acid, and allowing the components to react to form a solution comprising performic acid and said second peroxy acid, the amount of peroxy acids being at least 5% by weight. The invention also relates to a storable solution comprising performic acid and said second peroxy acid. The solution can be used as a disinfecting agent for controlling micro-organisms.09-03-2009
20100168233TERBINAFINE FORMULATION - The present invention provides a pharmaceutical composition comprising as the active agent a terbinafine compound, water, and at least one water-soluble or water-miscible nonionic surfactant, wherein the terbinafine compound has at least one form selected from the group consisting of free base form, acid addition salt form, ionic form, and combinations thereof; and wherein substantially no alcohol is present.07-01-2010
20110288172DERMATOLOGICAL COMPOSITIONS AND METHODS - Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.11-24-2011
20090182048Compounds Useful For Treating Neurological Disorders - The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided.07-16-2009
20090298939Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals - The disclosure provides a method for isolating the bioactive component of the water-soluble extract of 12-03-2009
20100120913RESIN CATALYZED AND STABILIZED PERACID COMPOSITIONS AND ASSOCIATED METHODS - Methods, compositions, and system for making and stabilizing peracids in peracid-containing compositions are provided. The method of making can include the contacting of a cationic exchange resin with a carboxylic acid and hydrogen peroxide containing solution and maintaining the peracid in contact with the solution for a period of at least 24 hours to form a peracid. The solution to cationic exchange resin weight ratio used in the method is at least 10:1 w/w. The method of stabilizing can similarly include the maintaining the contact between the peracid-containing composition in contact with the cationic exchange resin during the storage of the peracid-containing composition. The methods and systems are particularly useful for peracid-containing disinfectant compositions.05-13-2010
20100081716PROCESS FOR PRODUCTION OF ETHER CARBOXYLATES - The present invention relates to a process for producing an ether carboxylate which includes the steps of (1) reacting an aliphatic monohydric alcohol with an alkylene oxide in the presence of an alkali catalyst; (2) neutralizing a reaction solution obtained in the step (1) with an acid such as hydroxycarboxylic acids to obtain an ether alcohol; and (3-1) reacting the obtained ether alcohol with a monohalogenofatty acid or a salt thereof and an alkali metal hydroxide, or (3-2) subjecting the obtained ether alcohol to catalytic oxidation reaction in the presence of a catalyst. The obtained ether carboxylate has a less odor and a high quality and is therefore suitably used in the applications such as cosmetics and toiletries.04-01-2010
20100099763TRITERPENE COMPOUNDS WHICH ARE EFFECTIVE ON IMPROVEMENT OF BRAIN FUNCTION - The present invention relates to the triterpene compounds improving in brain functions. In particular, the present invention relates to a novel use of the triterpene compounds represented by the Formula 1 for improving decreased memory and a pharmaceutical composition for improving brain functions comprising the triterpene compounds represented by the Formula 1.04-22-2010
20090275656Medicinal Compositions of Salts, Chelates and/or Free Acids of Alpha Hydroxyl Organic Acids and Related Processes and Methods - Processes are described for the production of an isolated medicinal composition for administration to mammals which comprises an effective amount of a free acid, salt or chelate of at least one naturally occurring form of an alpha hydroxyl organic acid comprising combining at least one naturally occurring form of an alpha hydroxy organic acid with an amount of base in an aqueous solution, wherein a total content of alpha hydroxyl organic acids amounts to between about 0.5% and about 35% w/w of the solution, for a time to hydrolyse substantially all forms of alpha hydroxyl organic acids present, neutralizing the solution to a pH between about 6.9 and about 7.6 to yield a free acid, salt or chelate of free acids of substantially all naturally occurring forms of alpha hydroxyl organic acids, and optionally lyophilizing the solution to produce an isolated medicinal composition. Compositions produced by these processes are disclosed and claimed. Method are described of enhancing DNA repair, enhancing an immune response, controlling inflammation, or inhibiting the progress of a tumor, comprising administering an effective amount of a composition produced by the processes described herein.11-05-2009
20080207754Method and apparatus for palatable prevention of acid reflux - A method and applicators for preventing or reducing acid reflux (or “GERD”) by delivering a proper dose of vinegar directly to the back of the throat without exposing the taste buds, and immediately followed by a shot of water or other pleasant tasting chaser to wash it down. One applicator generally comprises a joined pair of sealed flexible pouches each sealed by a seal that may be burst open on the application of pressure to the pouches in order to dispense the product therein. The first pouch is filled with a dose of undiluted apple cider vinegar (approximately 5 to 10 cc) and the second pouch is filled with a liquid chaser, usually distilled water. Another applicator generally comprises a drinking vessel defined by two side-by-side receptacles, and pair of fixedly attached straws each entering a corresponding receptacle. The straw entering the chaser is oriented at a fixed angle greater than the straw entering the vinegar so that vinegar pours first followed by the chaser. In use, the vessel is lifted to the mouth with both straws disposed at the back of the throat, and the vessel is tilted so that the vinegar receptacle pours first, followed immediately by the chaser. This results in the vinegar pouring directly down the throat without exposing the taste buds, and being immediately followed by the chaser to wash it down.08-28-2008
20090298941ANTI-ADIPOCYTE FATTY ACID-BINDING PROTEIN (AP2), ANTI-FLAP AND ANTI-CYSLT1 RECEPTOR HERBAL COMPOSITIONS - Herbal compositions having anti-adipocyte fatty acid-binding protein (aP2), anti-5-lipoxygenase-activating protein (FLAP) and anti-Cysteinyl Leukotriene (CysLT)-1 receptor expression activity contain an extract of 12-03-2009
20090042984Cool-Pet System - Included is an invention that deals with animal and pet nuisance, behavior control, obedience training, urinary and potty training, and repellent/discouragement method where a solution having vinegar and flavors being dispensed from a spray bottle is found to be effective in stopping or discouraging dogs, birds or animals from being noisy, being hyperactive, and behaving badly. The solution is also useful for obedience training purposes and can also be applied as a repellent/discouragement method when sprayed onto desired spots or onto the animal.02-12-2009
20090298938USE OF SEMI SYNTHETIC ANALOGUES OF BOSWELLIC ACIDS FOR ANTICANCER ACTIVITY - The present invention relates to use of compounds of general formula 1 for anticancerous activity, wherein the said compound being derived semi-synthetically from natural triterpenoic acids known as boswellic acids by the induction of apoptosis thereof cytotoxicity and anti-cancer activity displayed by semi-synthetic analogues of natural triterpenes, known as Boswellic acids. These compounds may be used for the treatment of cancer, alone or in combination with pharmaceutically acceptable or other carriers, displaying cytotoxicity and anti-cancer activity for colon, prostrate, liver, breast, central nervous system (CNS), leukemia and malignancy of other tissues, including ascites and solid tumors. The cancer cell death is mediated by induction of apoptosis and inhibition of cell proliferation at specific doses.12-03-2009
20120059059METHOD FOR INHIBITING ACTIVITY AND/OR EXPRESSION OF MATRIX METALLOPROTEINASE, INHIBITING PHOSPHORYLATION OF MITOGEN-ACTIVATED PROTEIN KINASE, AND/OR PROMOTING EXPRESSION OF COLLAGEN USING TORMENTIC ACID - A method for inhibiting the activity of matrix metalloproteinase (MMP), inhibiting the expression of matrix metalloproteinase, inhibiting the phosphorylation of mitogen-activated protein kinase (MAPK), and/or promoting the expression of collagen in a mammal is provided. The method comprises administrating to the mammal an effective amount of an active component selected from a group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound, and combinations thereof:03-08-2012
200901495364-OXO-(ISO)TRETINOIN FOR THE TOPICAL TREATMENT OF SEVERE DERMATOLOGICAL DISORDERS - A method for the treatment of dermatological disorders wherein such treatment includes at least one of inhibiting lipogenesis in the skin and reducing the size of sebaceous glands, said treatment comprising the topical administration of a compound selected from 4-oxo-tretinoin, 4-oxo-isotretinoin and mixtures thereof to a patient in need thereof. The method of the invention is particularly advantageous for the topical treatment of severe acne and seborrhoea.06-11-2009
20090264526Natural ligand of G protein coupled receptor RCC356 and uses thereof - The invention relates to the identification of isovaleric acid as a natural ligand of the RCC356 G-protein coupled receptor (GPCR). The invention encompasses the use of the interaction of RCC356 polypeptides and isovaleric acid as the basis of screening assays for agents that modulate the activity of the RCC356 receptor. The invention also encompasses diagnostic and other assays performed based upon the RCC356/isovaleric acid interaction, as well as kits for performing diagnostic and screening assays.10-22-2009
20080269328Effects of low n-6:n-3 fatty acid ratio from two dietary sources on plasma and tissue lipid composition - Health benefits from low n-6:n-3 fatty acid (FA) ratio on cardiovascular risk have been shown. However, the impact of the source of n-3 FAs has not been fully investigated. Our purpose was to investigate cardiovascular benefits of oils with a low ratio of n-6:n-3 FAs, but different sources of n-3 FAs. Mice were divided into 3 groups (n=7) and fed a diet supplemented with either a fish or flaxseed oil-based ‘designer oils’ with an approximate n-6:n-3 FA ratio of 2/1 or with a safflower-oil-based diet with a ratio of 25/1, for 16 weeks. Plasma lipids and fatty acid profile of the liver and heart tissues were characterized. Plasma cholesterol levels were reduced in both fish and flax groups by 27% and 36%, respectively, as compared to controls at endpoint. The levels of EPA and DHA in liver phospholipids were significantly increased in both fish and flax groups as compared to the control group, with more profound increases in the fish group. Arachidonic acid levels were similarly decreased in the liver tissues from both fish and flax groups as compared to controls. Our data indicates that health benefits may be achieved by lowering dietary n-6:n-3 FA even in a high fat diet medium.10-30-2008
20090118369Use of CIS-9, Trans-11 Isomer of Conjugated Lineoleic Acid - A composition and medicament comprising the cis-9, trans-11 isomer of conjugated linoleic acid for treating inflammatory diseases, including asthma, is provided. A method for inhibiting the proliferation of human or animal cells of the immune systems involved in an immune response including administering the cis-9, trans-11 isomer of conjugated linoleic acid to a patient is also provided. A nutritional, functional food, or dietary supplement including the cis-9, trans-11 isomer of conjugated linoleic acid is also provided.05-07-2009
20090023809HYDROGEN CYANAMIDE PESTICIDE FORMULATIONS - Agricultural crops are protected from the growth of undesirable vegetation as well as nematode and insect infestations, by the application of hydrogen cyanamide in combination with a short-chain, water-soluble monocarboxylic acid, with improved pesticidal effect.01-22-2009
20090082445GOSSYPOL CO-CRYSTALS AND THE USE THEREOF - This invention relates to compositions comprising co-crystals of (−)-gossypol with a C03-26-2009
20090203782Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders - This invention relates to a method of treating certain disorders by administering a compound of the formula 108-13-2009
20090209643METHOD FOR MODULATING STEM CELL GROWTH - In one embodiment, provided is a composition comprising a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is a composition comprising a prostaglandin compound for, which comprises a prostaglandin compound for modulating proliferation and/or differentiation of stem cells of a mammalian subject, in which the stem cells are contacted directly or indirectly with the composition of the invention.08-20-2009
20090247631Enzymatic Production Of Peracids Using Perhydrolytic Enzymes - A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides substrates. The concentrated peracid solution produced is sufficient for use in a variety of disinfection and/or bleaching applications.10-01-2009
20090239948Enzymatic Production Of Peracids Using Perhydrolytic Enzymes - A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides substrates. The concentrated peracid solution produced is sufficient for use in a variety of disinfection and/or bleaching applications.09-24-2009
20090253790Dairy Composition with Probiotics and Anti-Microbial System - Dairy compositions are provided having a high pH, of about 4.8 to about 6.2, comprising desirable probiotic cultures as well as an anti-microbial system for inhibiting undesirable pathogenic and/or spoilage microbial growth without significantly reducing the beneficial effect of the probiotic cultures.10-08-2009
20100152292Production of Peracids Using An Enzyme Having Perhydrolysis Activity - A method is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity derived from 06-17-2010
20100190858Pharmaceutical Formulations Containing Lipoic Acid Derivatives - Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.07-29-2010
20100179219Plane Tree Cream, Method for the Production Thereof and Use - In order to prevent betulinic acid from crystallizing in a galenic preparation containing water, a plane tree cream in the form of a stable emulsion containing oil and water is proposed, which is characterized by a content of 2 to 10% by weight of a plane tree extract obtained from the bark of plane trees, 0.1 to 9.9% by weight of glycerol, 0.1 to 1.9% by weight of a gelatinizing agent and 5 to 15% by weight of a preservative. The plane tree extract used is obtained by extracting plane tree bark with a low alkanol. The plane tree cream is used for the topical treatment of the skin, including the mucous membranes.07-15-2010
20100184860Novel Carboxylic Acid and Antidepressant Composition Containing the Same as Active Ingredient - The present invention provides a novel compound and antidepressant composition that can be effectively used for improving depressed mood and depressed state, particularly for depressed mood and depressed state in menopausal women. The compound of the present invention is represented by the following formula (1):07-22-2010
20100261792Alpha-Keto Alkylperacids and Methods For Producing and Using the Same - The present invention provides α-keto alkylperacids and methods for producing and using the same. In particular, α-keto alkylperacids are useful as antimicrobial agents.10-14-2010
20100184859MEDICAMENT HAVING PROMOTING ACTION ON HEPATOCYTE PROLIFERATION - A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient.07-22-2010
20110060044ALIPHATIC ACID-CONTAINING N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding an aliphatic acid to said formulation.03-10-2011
20100227923PREVENTIVE/REMEDY FOR URINARY CALCULOSIS - The present invention relates to a prophylactic/therapeutic drug for urolithiasis containing as an active ingredient L-aldonic acid, a salt thereof, or a lactone form thereof.09-09-2010
20100240751Methods - A perfluoroctanoic acid or a salt or an ester thereof; perfluorosuberic acid, perfluoroheptanoic acid, perfluorohexanoic acid, perfluoropentanoic acid, perfluorobutanoic acid or perfluoropropionic acid or a salt or an ester any thereof; or perfluoroctane are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipid or eicosanoid status or function may be desirable.09-23-2010
20100240752Aqueous Acidic Hard Surface Cleaning and Disinfecting Compositions - A highly aqueous liquid acidic hard surface treatment composition having a pH of about 3.5 or less which necessarily comprises: 09-23-2010
20100144877Synergistic Enhancement of Calcium Propionate - A novel composition comprised of a monocarboxylic fatty acid synergistically enhanced with a dual quaternary ammonium compound to provide immediate fungal and sporicidal destruction with long term residual resistance.06-10-2010
20100204325VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition.08-12-2010
20110028550COMPOSITIONS AND METHODS FOR CONTROL OF LISTERIA MONOCYTOGENES - The present invention relates to methods for inhibiting the growth of pathogenic microbes in food products. In an embodiment the invention is a preservative composition including lactic acid or a salt thereof, acetic acid or a salt thereof, and propionic acid or a salt thereof. In an embodiment, the invention is a food product including lactic acid or a salt thereof, acetic acid or a salt thereof, and propionic acid or a salt thereof. In an embodiment, the invention includes a method of making a food product including adding an antimicrobial preservative composition to a composition comprising a meat, the antimicrobial preservative composition comprising lactic acid or a salt thereof, propionic acid or a salt thereof, and acetic acid or a salt thereof. Other embodiments are also included herein.02-03-2011
20110028549USE OF A MONOTERPENE TO TREAT OR PREVENT STRESS - The present invention relates to the use of a monoterpene for the prevention, alleviation or treatment of a pathological or non-pathological stress condition of an individual.02-03-2011
20110028551NOVEL PROCESS FOR THE PREPARATION OF SODIUM GAMMA-HYDROXYBUTYRATE - The present invention is directed to a process for the preparation of the saponification products of lactones, preferably three- to eight-membered lactones. The present invention is also directed to a process for the preparation of compounds having general formula (I): wherein M is selected from the group consisting of cationic species, preferably metal cations (even more preferably Na), from a compound having the formula (II): comprising reacting a compound having formula (II) with a suitable hydroxide salt (M-OH) (III) such as, preferably, sodium hydroxide, in an aqueous medium. The reaction preferably utilizes a continuous process method for the substantial consumption of reagent and continuous, semi-continuous, and/or batch-wise processing for final consumption of reagent.02-03-2011
20090253789Preventive/Remedy for Arteriosclerotic Disease and Method of Evaluating Therapeutic Procedure - There is provided an evaluation method of effect of a remedy or a therapeutic procedure for atherosclerosis directly or indirectly acting on a substance having a nature of exacerbating atherosclerosis (particularly, a protein) and being present in an atherosclerotic lesion to improve the atherosclerotic lesion, which comprises performing an evaluation by, regarding respective atherosclerotic lesion samples of a mammal origin collected from an administration- or application-group of the remedy or therapeutic procedure, and from a non-administration- or non-application-group, comparing a value of one group corresponding to strength of an atherosclerosis-exacerbating activity of the substance (for example, a pharmacological activity such as an enzyme activity) present in the sample and corrected by an amount of a correction marker in the atherosclerotic lesion, with that of the other group, said amount of the correction maker varying correlating with an amount of the substance in the atherosclerotic lesion and being not influenced by the remedy or therapeutic procedure to be evaluated.10-08-2009
20090069424TGF-alpha expression inhibitors - An inhibitor against TGF-α expression and an inhibitor against transformation of a hepatitis and/or cirrhosis cell which comprise as an active ingredient a polyprenyl compound such as a polyprenyl carboxylic acid (for example, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid). The inhibitor can be used as an inhibitor against onset, recurrence (second oncogenesis), and malignant alteration of carcinoma in a liver.03-12-2009
20130143965MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.06-06-2013
20100168234PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.07-01-2010
20100056630COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF FIRE BLIGHT - The invention relates to an agent for treating and/or preventing fire blight, particularly present in wood and fruit trees, comprising formic acid and/or a salt of formic acid, particularly calcium formiate as an active component. Further disclosed is the use of formic acid and/or a salt of formic acid, particularly calcium formiate as an active component in herbicides, particularly for treating and/or preventing fire blight, and the use of formic acid and/or a salt of formic acid, particularly calcium formiate, for the production of an agent for treating and/or preventing fire blight.03-04-2010
20110039929MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.02-17-2011
20110086918Broad Spectrum Preservation Blends - A composition having effective broad spectrum preservation activity comprising benzyl alcohol, salicylic acid, sorbic acid and a compound selected from the group consisting of 1,3-propanediol, glycerin and combinations thereof.04-14-2011
20110178175METHOD FOR PRODUCING MECHANICALLY ACTIVATED AMORPHOUS AND AMORPHOCRYSTALLINE COMPOUNDS OF GLUCONIC ACID CALCIUM SALT - The invention relates to the creation of mechanically activated amorphous and amorphocrystalline compounds and compositions of a gluconic acid calcium salt, pharmaceutical preparations based thereon, a method for producing same and use for treatment of a wide range of diseases caused by disorders of calcium metabolism in an organism. A concept of the invention, as being claimed and as set forth in the application, consists in that the crystalline gluconic acid calcium salt or its compound with excipients is treated in grinding activator devices either up to the input specific energy value of not greater than 10.4 kJ/g and achieving an amorphocrystalline state or up to the input specific energy value of no less than 10.5 kJ/g and achieving an amorphous state. The obtainable agents are assessed by means of X-ray diffraction, IR, NMR, EPR spectroscopy, mass- or chromato-mass-spectrometry, and a differential thermal analysis. The mechanically activated amorphous and amorphocrystalline compounds and compositions are used as an active principle for preparing pharmaceutical preparations used for therapeutic, therapeutic-preventive and hygienic purposes. The pharmaceutical preparations comprising a therapeutically effective amount of active ingredient are used perorally 1-6 times daily, in dosages of 0.2-6 g, a course of at least 1 month. The invention can be used in medical and food industries in the production of biologically active agents, therapeutic-prophylactic means, medicinals and in practical medicine in treatment of acute osseous, dental and other diseases related to disorders of calcium metabolism in the organism.07-21-2011
20110152370PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 06-23-2011
20100056629RETROVIRUS-INFECTION INHIBITOR - An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives thereof.03-04-2010
20100056631ANTIALLERGENIC COMPOSITION - An antiallergenic composition comprising 3-hydroxybutyric acid and/or a salt thereof. The antiallergenic composition is safe.03-04-2010
20110098357VAGINAL SUPPOSITORY COMPRISING LACTIC ACID - The present invention relates to a vaginal suppository comprising an inert vehicle and lactic acid or a salt thereof for the treatment and/or prophylaxis of disorders in the urogenital tract. It also relates to the use of such a suppository for the production of a medicament for the treatment and/or prophylaxis of disorders in the urogenital tract as well as to a method for the treatment and/or prophylaxis of disorders in the urogenital tract.04-28-2011
20120065262COMPOSITION FOR PREVENTING HAIR LOSS OR FOR STIMULATING HAIR GROWTH - Provided is a composition for preventing hair loss or promoting hair growth including valproic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be applied to various industrial fields, including pharmaceutical, cosmetic and beauty aid industries.03-15-2012
20120172438GLYCYRRHETINIC ACID ESTER DERIVATIVE SYNTHESIS METHOD AND DEOXOGLYCYRRHETINIC ACID ESTER COMPOUND - A compound represented by formula II, a preparation method, and uses thereof in treating liver damage and inflammation and so on are disclosed. A method for preparing glycyrrhetinic acid derivatives are also disclosed. In the compound represented by formula II, R07-05-2012
20120172437CONTINUOUS ON-LINE ADJUSTABLE DISINFECTANT/SANITIZER/BLEACH GENERATOR - Methods and systems for on-site, continuous generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ generated peroxycarboxylic acids and peroxycarboxylic acid forming compositions are also disclosed.07-05-2012
20110152369PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 06-23-2011
20110152368PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 06-23-2011
20090312420Production Of Peracids Using An Enzyme Having Perhydrolysis Activity - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.12-17-2009
20120202879MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.08-09-2012
20090247632DERMATOLOGICAL COMPOSITIONS AND METHODS - Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.10-01-2009
20090118370METHOD OF TREATING CANCER USING DICHLOROACETATE - The invention relates to the use of dichloroacetate and chemical equivalents thereof for the treatment of cancer by inducing apoptosis or reversing apoptosis-resistance in a cell Preferably, the dosage is 10-100 mg/kg Preferably, sodium dichloroacetate is used. The dichloroacetate may optionally be given in combination with a pro-apoptotic agent and/or a chemotherapeutic agent Preferably, the cancers treated are non-small cell lung cancer, glioblastoma and breast carcinoma.05-07-2009
20110054025USE OF A PENTACYCLIC TRITERPENE IN A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS - Oleanolic acid (3β-hiydroxyolean-12-en-28-oic acid) is a pentacyclic triterpene occurring in a large number of medicinal plants. The present invention is directed to the pharmacological application of the oleanolic acid, alone or in combination with other substances, in the treatment or prophylaxis of neurodegenerative diseases such as multiple sclerosis. The inventors have found that oleanolic acid, intraperitoneally administered once daily, reduces significantly the immuno-inflammatory and neurological symptoms associated with the experimental autoimmune encephalomyelitis, an experimental model of multiple sclerosis, delaying the onset and reducing the progression of the disease.03-03-2011
20100331412Two container skin care product - A skin product for improving the skin includes a first container containing a first product, the first product including alpha hydroxy acid, and second container containing a second product, the second product including a combination of humectants, moisturizers and an AHA (glycolic acid) formulation.12-30-2010
20110263707MOSQUITO REPELLENT - The present invention relates to a mosquito repellent comprises at least one or more selected from the group consisting of neric acid and derivatives thereof in an effective amount to repel mosquito.10-27-2011
20110263706METHOD FOR ENHANCING THE DNA REPAIR PROCESS, TREATING DISORDERS ASSOCIATED WITH THE DNA REPAIR PROCESS, ENHANCING ANTITUMOR RESPONSE AND TREATING DISORDERS ASSOCIATED WITH ANTI-TUMOR RESPONSE IN MAMMALS BY ADMINISTERING PRUIFIED QUINIC ACID AND/OR CARBOXY ALKYL ESTER - The disclosure provides a method for isolating the bioactive component of the water-soluble extract of 10-27-2011
20100168235PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.07-01-2010
20110136908PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 06-09-2011
20110136907PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 06-09-2011
20110071223BODY COSMETICS FOR WETTED SKIN - A body cosmetic for application to wetted skin after bathing, and the like, which provide high moisturizing effects, spread well to all over the body, and are easy to apply.03-24-2011
20100022644PEROXYCARBOXYLIC ACID COMPOSITIONS WITH REDUCED ODOR - The present invention relates to compositions of peroxycarboxylic acid that have reduced odor compared to conventional peroxycarboxylic acid compositions, methods employing these reduced-odor compositions, and methods of making these compositions. Typically, the reduced-odor compositions include an amine oxide surfactant.01-28-2010
20100016429Enzymatic Production Of Peracids Using Perhydrolytic Enzymes - A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides substrates. The concentrated peracid solution produced is sufficient for use in a variety of disinfection and/or bleaching applications.01-21-2010
20090105339Curative drug for neurodegenerative diseases - A compound is prepared based on Formula 1:04-23-2009
20090131521Aqueous retinoid and benzoyl peroxide gel - Embodiments of this invention relate to a composition containing both benzoyl peroxide and a retinoid. Additionally, it relates to the treatment of acne vulgaris by applying an aqueous gel comprising BPO and a retinoid.05-21-2009
20080234374Compositions and method for removing hair - The invention encompasses a composition for hair removal comprising at least one organic hair follicle penetrating agent and at least one enzyme inhibitor for the purpose of achieving permanent hair follicle inactivation, and methods for hair removal using the same.09-25-2008
20090264527METHOD FOR STABILIZING RETINOIC ACID, RETINOIC ACID CONTAINING COMPOSITION, AND METHOD OF USING A RETINOIC ACID CONTAINING COMPOSITION - A method for stabilizing retinoic acid is provided. The method includes a step of mixing retinoic acid with a hydrophobic polymer/hydrophilic polymer adduct in the presence of an oxygen containing atmosphere to form a retinoic acid containing composition. The hydrophobic polymer/hydrophilic polymer adduct comprises a poly(vinylpyrrolidone/alkylene) polymer and a polymer comprising repeating carboxylic acid groups, hydroxyl groups, or a mixture of carboxylic acid groups and hydroxyl groups. A retinoic acid containing composition and a method of using a retinoic acid containing composition are provided.10-22-2009
20110306667Stabilization Of Perhydrolases - Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided.12-15-2011
20090298940All Natural Antifungal And Antimicrobial Composition And Method Thereof - In accordance with the present invention, there is provided a novel all natural antifungal composition and method. There is further provided a novel all natural antibiotic and antimicrobial composition and method. There is provided an antifungal and/or antimicrobial composition and method that may be used to treat conditions caused by gram negative bacteria, viruses and fungi, especially molds and mycocytes, with a composition comprising potassium sorbate, lecithin, cellulose, and wax. There is provided a composition and method for administration directly to dermal, oral, gastrointestinal and/or nasal tissues that are affected by molds and mycocytes.12-03-2009
20100331413Therapeutic Formulations Based on Asiatic Acid and Selected Salts Thereof - A highly pure asiaticoside and a pharmaceutical grade asiatic acid can be prepared, along with salts of asiatic acid, for use in formulating therapeutic compositions that are suitable for treating arthritis, psoriasis and other inflammatory diseases, as well as pulmonary fibrosis, diabetic nephropathy, and other fibrotic diseases.12-30-2010
20100280114Primers and primer sets for use in methods to detect the presence of acidovorax avenae subsp. citrulli - The present invention relates to oligonucleotide primers and primer sets that can be used to identify the bacterial pathogen 11-04-2010
20100125104Alpha-Keto Peracids and Methods For Producing and Using the Same - The present invention provides α-keto peracids and methods for producing and using the same. In particular, α-keto peracids are useful as antimicrobial agents.05-20-2010
20120115953Self-Neutralizing Acid Peel for Dermatologic Use - A dermatologic peel comprising alpha hydroxyl acid and metal hydroxide nanocomplexes as neutralizing agents to continually reduce the activity of the system when the acid and neutralizer components are mixed. For example, a 30% glycolic acid gel mixed with a fluidized magaldrate neutralizer can be applied to the skin and will self-neutralize to a skin-compatible pH within a few minutes, effectively exfoliating the skin without a separate neutralization step. The peel is advantageously applied from a two-component system that mixes the components.05-10-2012
20120016025PERHYDROLASES FOR ENZYMATIC PERACID GENERATION - Disclosed herein are variants enzymes that are structurally classified as CE-7 enzymes and have perhydrolysis activity. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned variant enzymes as well as methods and compositions comprising the variant enzymes. Further, disinfectant formulations comprising the peroxycarboxylic acids produced by the processes described herein are provided.01-19-2012
20120115952METHOD FOR IMPROVING THE SENSORY PROPERTIES AND RESISTANCE OF FOOD AND DRINK PRODUCTS TO MICRO-ORGANISMS - A method for improving the sensory properties and resistance of food and drink products, especially uncured meat products, to various kinds of micro-organisms and in particular food spoilage and food poisoning bacteria includes contacting the food or drink product with a composition comprising alkali metal salts having as anions propionate and a co-anion selected from lactate, acetate, and combinations thereof, and as cations potassium and hydrogen, wherein the weight-based ratio of lactate/propionate is in the range of 0 to 20 and the weight-based ratio of acetate/propionate is in the range of 0.05 to 3.5.05-10-2012
20120115951PROTECTIVE ACTION OF SEROFENDIC ACID ON CARDIAC MUSCLE - A cardiac myocyte protective agent, comprising a compound represented by the formula (Ia) below, a pharmaceutically acceptable salt thereof, or a solvate thereof:05-10-2012
20120059060VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition.03-08-2012
20120157527COSMETIC USE OF A JASMONIC ACID DERIVATIVE FOR TREATING THE HAIR AND THE SCALP - The present invention relates to the cosmetic use of jasmonic acid derivatives of formula (I)06-21-2012
20120071555COMPOSITIONS OF ABSCISIC ACID FOR ANIMAL HEALTH - The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of using the same for improving the health and offspring mortality of animals.03-22-2012
20120309829COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF - The invention encompasses compositions and methods for maintaining or promoting a healthy body composition in a companion animal, which comprises feeding the animal an edible composition comprising one or more pyruvate in an amount effective to maintain or promote the healthy body composition, wherein maintaining or promoting the healthy body composition comprises controlling the animal's weight, for example, loss of weight or body fat, or increased percentage of lean muscle mass.12-06-2012
20120309828COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF - The invention encompasses compositions and methods for treating or preventing kidney disease in a companion animal, wherein the compositions and methods include feeding the companion animal an edible composition including at least one pyruvate or salt thereof.12-06-2012
20110065792NOVEL SUBSTANCES ANALOGOUS TO MK8383 AND AGRICULTURAL AND HORTICULTURAL DISEASE CONTROL AGENTS - An objective of the present invention is to provide agricultural and horticultural disease control agents that have potent control effect against plant diseases and, at the same time, have high photostability. The agricultural and horticultural disease control agents comprise a novel substance analogous to MK8383 as an active ingredient.03-17-2011
20110105611USE OF MASLINIC ACID FOR THE TREATMENT OF PATHOLOGIES AND THEIR SYMPTOMS THROUGH THE INHIBITION OF COX-2 - The invention relates to the use of maslinic acid or natural, synthetic or semi-synthetic maslinic-rich mixtures or of a composition containing said acid for the treatment of pathological processes associated with COX-2 activation, intended, inter alia, for the symptomatic and/or regenerative treatment of arthrosis, rheumatoid arthritis, fibromyalgia, sciatica and other articular disorders that are difficult to diagnose. The invention also relates to the topical administration thereof.05-05-2011
20100093861TREATMENT OF INSULIN RESISTANCE OR DISEASES ASSOCIATED WITH INSULIN RESISTANCE - The present invention relates to the use of a substance with the core structure of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the manufacture of a composition for the treatment of insulin resistance or diseases associated with insulin resistance, preferably in human subject in a daily dosage in a range of from about 5 mg to about 1500 mg. The invention furthermore relates to a method of treating insulin resistance or diseases associated with insulin resistance in a mammal, said method comprises administering to said mamma, preferably a human subject, a substance with the core structure of formula (I), preferably in a daily dosage in a range from about 5 mg to about 1500 mg. The substance is preferably isosteviol or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. Examples of diseases associated with insulin resistance are e.g. type 2 diabetes mellitus, insulin resistance syndrome, impaired glucose tolerance, the metabolic syndrome, hyperglycemia, hyperinsulinemia, arteriosclerosis, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, dyslipidemia, obesity, central obesity, polycystic ovarian syndrome, hypercoagulability, hypertension, microalbuminuria, or any combinations thereof.04-15-2010
20100093860HYDROXYBUTYRATE AND POLY-HYDROXYBUTYRATE AS COMPONENTS OF ANIMAL FEED OR FEED ADDITIVES - This invention relates to the use of hydroxybutyrate and poly hydroxybutyrate as components of animal feed or feed additives, as well as to compositions, feed additives and feed containing them. The inventors surprisingly found that hydroxybutyrate and poly-hydroxybutyrate, preferably 3-hydroxybutyrate and poly-3-hydroxybutyrate, have a great potential for use in animal feed for modulation of the gut flora. More precisely, it has been found that poly-3-hydroxybutyrate or a microbial strain capable for producing poly-3-hydroxybutyrate can be used as a potential growth promoter or gut flora modulator by releasing SCFA, preferably 3-hydroxy butyric acid, in the gut micro flora. Further, the inventors found that 3-hydroxybutyrate and poly-3-hydroxybutyrate have a great potential for suppressing or inhibiting pathogenic bacteria in the gastro intestinal tract, e.g. have a antimicrobial activity against strains of 04-15-2010
20120122979CONTROL OF ENZYMATIC PERACID GENERATION - A process is provided for producing target concentrations of peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity under conditions where control of reaction pH by selection of buffer concentration and concentration of perhydrolase and reactants produces a targeted concentration of peroxycarboxylic acids. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided, as are corresponding methods of use.05-17-2012
20100249231HSP90 Inhibitors of Protein-Protein Interaction HSP90 Chaperone Complexes and Therapeutic Uses Thereof - A novel Hsp90 inhibitor that disrupts protein-protein interaction in a Hsp90 superchaperone complex without blocking ATP binding and methods for treating diseases such as pancreatic cancer are disclosed.09-30-2010
20120165407STRATEGY FOR ON-SITE IN SITU GENERATION OF OXIDIZING COMPOUNDS AND APPLICATION OF THE OXIDIZING COMPOUND FOR MICROBIAL CONTROL - The invention provides a method of controlling biological fouling of water containing items. The method involves combining at least two reactants, a peroxygen source and an acyl group donor to form peracetic acid. Because the peracetic acid can be made in situ, the entire sum of its short lifespan can be used controlling biocidal fouling and storage and transport is simplified. The invention further facilitates the ease of controlling biocidal fouling by allowing the injection of the biocidal agent in liquid form, in a non-acidic environment, and without the need for any halogen. This allows the inventive biocide to be used with chemistries for which prior art biocides are inapplicable.06-28-2012
20120220658Method for Treating Sepsis or Septic Shock - The present invention is a method for treating sepsis or septic shock using Lipoxin A4.08-30-2012
20120220657SYNERGISTIC ANTI-INFLAMMATORY AND ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS - Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and anti-oxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally containing glucosamine, resveratrol, garlic extract, chondroitin, methlysulphonymethane, bromelain, serratiopeptidase, quercitine, gallic acid, caffeic acid, green tea extract, aspirin and ibuprofen.08-30-2012
20120129935NUTRITION WITH LIPIDS AND NON-DIGESTIBLE SACCHARIDES - The invention relates to a liquid nutrition comprising short chain fatty acyl chains and a non-digestible, fermentable saccharide. The composition is particular suitable for use as an infant nutrition. The composition is also suitable for treatment and/or prevention of gut barrier related disorders.05-24-2012
20090012163Compositions containing Mg/Zn/F-CaP plus inhibitors of pro-inflammatory cytokines (alpha ketoalkanoic acid compound) for osteoporosis prevention, therapy and treatment of bone diseases - A method is described for the treatment of bone disease by oral dosing of a patient with an inhibitor(s) or pro-inflammatory Cytokines which are comprised of a combination of alpha ketoalkanoic acid admixed in a pharmaceutically acceptable carrier with calcium/phosphate/magnesium/zinc or strontium salt compound ion—a hydroxyapatite matrix.01-08-2009
20100197786Insect-repellent formulations - An insect repellent aqueous formulation comprising a combination of at least two essential oils, citrus peel tincture, and vinegar.08-05-2010
20100048703Hair care product - A substance having a testosterone 5α-reductase inhibiting action, a hair papilla cell growth promoting action, a fibroblast growth factor-7 production promoting action, a vascular endothelial growth factor production promoting action or a bone morphogenetic protein-2 production promoting action, and a hair care product having this substance blended therein. A hair growth tonic, a testosterone 5α-reductase inhibitor, a hair papilla cell growth promoter, a fibroblast growth factor-7 production promoter, a vascular endothelial growth factor production promoter and a bone morphogenetic protein-2 production promoter each having this substance, such as corosolic acid, as an active ingredient thereof.02-25-2010
20120178811METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE TO REDUCE THE RISK OF INFECTION IN AN ELDERLY INDIVIDUAL - Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of β-hydroxy-β-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.07-12-2012
20120178810Extended release formulation of an antiepileptic agent - The present invention relates to an extended release formulation of an antiepileptic agent. More particularly, the present invention relates to an extended release formulation of divalproex sodium. The present invention also relates to a process for the preparation of extended release formulation of divalproex sodium.07-12-2012
20130172415TRICLOSAN-FREE ANTIBACTERIAL SOAP - Disclosed herein is an antibacterial cleansing composition. The cleansing composition is free of triclosan and comprises lactic acid/lactate and ethyl alcohol. Lactic acid/lactate is present in the composition in an amount of about 5 weight percent (wt %) to about 15 wt %, based on the total weight of the composition. Ethyl alcohol is present in an amount of about 1 wt % to about 20 wt %, based on the total weight of the composition. The pH of the composition is about 4 to about 5. The triclosan-free cleansing composition according to the invention has broad spectrum antibacterial activity that equals or even surpasses comparable formulations containing triclosan.07-04-2013
20090137671METHODS OF TREATING METABOLIC DISORDERS - A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) β/δ of the cells.05-28-2009
20120259013LIQUID DOSAGE FORMS OF ISOTRETINOIN - The present invention relates to a pharmaceutical solution comprising isotretinoin or salts thereof. The present invention further relates to the processes for preparing such compositions.10-11-2012
20120259014TOPICAL RETNOID SOLUTIONS - The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and a process of preparing it.10-11-2012
20120322872SUGAR ESTER PERACID ON SITE GENERATOR AND FORMULATOR - Methods and systems for on-site generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ generated peroxycarboxylic acids and peroxycarboxylic acid forming compositions are also disclosed.12-20-2012
20120322873USE OF A BUFFER WITH A BIOCIDE PRECURSOR - Disclosed herein are biocidal compounds and compositions, methods of using said compounds and compositions, and systems and processes for their preparation. Particularly disclosed herein are in situ generated biocides stabilized with a buffer. The biocide may include in situ generated peracetic acid produced from a peroxygen source, an acyl group donor, and a buffer.12-20-2012
20120101161FATTY ACID ANALOGUES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISORDERS - The present invention relates to fatty acid analogues of the general formula R04-26-2012
20120289598COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF - The invention encompasses compositions and methods for treating or preventing a degenerative joint condition, wherein the compositions and methods include feeding the companion animal an edible composition including at least one pyruvate or salt thereof. The invention also encompasses methods for enhancing the palatability of an edible food composition including adding a palatability enhancing amount at least one pyruvate or salt thereof to the composition.11-15-2012
20100168237PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.07-01-2010
20100168236PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.07-01-2010
20130018099DEODORIZATION OF PERACIDS - The present invention relates to compositions of peracids, such as peroxycarboxylic acids, having reduced odor compared to conventional peracid compositions. The invention further relates to methods employing such compositions, and methods of making these compositions. Typically, the reduced-odor antimicrobial compositions include an alcohol for the esterification reaction to remove short- to mid-chain length malodorous carboxylic acids.01-17-2013
20130172416COMPOSITIONS COMPRISING ACIDIC EXTRACTS OF MASTIC GUM - The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating impaired neurological functions as well as wound and tissue repair.07-04-2013
20080249173Treatment of Apoptosis - A method is provided for treating a patient suffering from apoptosis of tissue comprising administering to that subject a therapeutically effective amount of one or more ketogenic compounds such that a physiological ketosis is produced sufficient to arrest said apoptosis. Preferably the apoptosis is of cerebral tissue such as that associated with acute intractible seizures, particularly with status epilepticus. The method is also applicable to apoptosis associated with administration of topic stuimuli for treatment of cancer, that produced by viral infections, autoimmune diseases or Aquired Immuno Defficiency Syndrome. The ketosis produced is a state in which levels of one or both of acetoacetate and (R)-3-hydroxybutyrate concentrations in the mood of the subject such that their total concentration in the blood is elevated above the normal fed levels to between 0.1 and 30 mM. Also provided is the use of ketogeic material to in the manufacture of a medicament for the treatment of apoptosis and pharmaceutical compositions for such treatment.10-09-2008
20100087528ENZYMATIC PERACID PRODUCTION USING A COSOLVENT - Disclosed herein are two-component enzymatic peracid generation systems and methods of using such systems wherein the first component comprises a formulation of at least one enzyme catalyst having perhydrolysis activity, a carboxylic acid ester substrate, and a cosolvent and wherein the second component comprises a source of peroxygen in water. The two components are combined to produce an aqueous peracid formulation useful as, e.g., a disinfecting or bleaching agent. Specifically, organic cosolvents are used to control the viscosity of a substrate-containing component and to enhance the solubility of the substrate in an aqueous reaction formulation without causing substantial loss of perhydrolytic activity of the enzyme catalyst.04-08-2010
20080221211METHOD OF TREATMENT OF NEUROLOGICAL INJURY OR CANCER BY ADMINISTRATION OF DICHLOROACETATE - A method for treating neurological injury or cancer in a patient includes administration of a therapeutically-effective amount of dichloroacetic acid (DCA), a therapeutically-effective amount of electromagnetic radiation, or both to the patient.09-11-2008
20120252893ANTIMICROBIAL FORMULATION - An anti-microbial composition for treating animal feed, comprising: 10-04-2012
20110269835Female Sex Pheromone of the Dogwood Borer (DWB), Synanthedon scitula, and Attraction Inhibitor (Antagonist) - A method for inhibiting (antagonizing) male 11-03-2011
20130096196PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN - An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle04-18-2013
20130102671PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 04-25-2013
20130102668PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 04-25-2013
20130102670PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 04-25-2013
20130102664PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 04-25-2013
20130102669PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 04-25-2013
20130102665PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 04-25-2013
20130102666PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 04-25-2013
20130102667PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 04-25-2013
20130102672PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 04-25-2013
20130158118Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the 06-20-2013
20130158117Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the 06-20-2013
20080200545PEELING PROCESS WITH SURFACTANTS - Process for the treatment of, e.g., visible and/or tactile irregularities of human skin, by applying topically, to the skin, a composition containing, in a physiologically acceptable medium, at least 5% by weight of one or more surfactants comprising at least one alkyl chain having from 6 to 16 carbon atoms.08-21-2008
20130150444MODIFIED RELEASE COMPOSITIONS OF MAGNESIUM VALPROATE - The present invention relates to a modified release pharmaceutical composition comprising therapeutically effective amounts of magnesium valproate and/or its pharmaceutically acceptable solvates or mixtures thereof and at least one rate controlling polymer. Rate controlling polymer is either hydrophilic or hydrophobic in nature. Mixture of the rate controlling material or more is also used to provide formulations of the present invention.06-13-2013
20130158115Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the 06-20-2013
20120283327PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF A HYDROCORTISONE DERIVATIVE DESIGNATED AS DEINA - The hydrocortisone derivative of formula (I), whose IUPAC name is 3-[3,5-Dihydroxy-3-(2-hydroxy-acetyl)-3a,6-dimethyl-7-oxo-dodecahydro-cyclo-penta[alpha]naphthalen-6-yl]-propionic acid, designated as Deina®, is used in the treatment of atrophic tissues, particularly skin, cartilage, connective, and mucosal tissues and scalp skin.11-08-2012
20130203849COMPOSITIONS AND METHODS OF TREATING EDIBLE MATTER AND SUBSTRATES THEREFOR - There are provided methods of treating edible matter comprising applying a composition comprising performic acid to the edible matter or a substrate therefor. Other embodiments are also disclosed.08-08-2013
20120071557ANIMAL FEED COMPOSITIONS OF ABSCISIC ACID - The invention relates to compositions comprising abscisic acid, and/or salts, and derivatives thereof, and methods of using the same for improving the health, growth, and feed efficiency of livestock and fish as well as the quantity of meat produced in livestock in particular.03-22-2012
20120071556PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS OF ABSCISIC ACID - The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of pharmaceutical and/or nutraceutical use.03-22-2012
20120071554DEUTERATED 2-PROPYLPENTANOIC ACID COMPOUNDS - Described herein are novel analogs of 2-propylpentanoic acid, pharmaceutical compositions comprising the same, and methods of using the same for the treatment of diseases or conditions that are beneficially treated by administering a GABAAergic transmission enhancer and/or a histone deacetylase (HDAC) inhibitor.03-22-2012

Patent applications in class Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.)

Patent applications in all subclasses Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.)